FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C	C. 20549
-----------------	----------

STATEMENT	OF CHANGES	S IN BENEFICIA	L OWNERSHIP

OMB APP	OMB APPROVAL									
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWN

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Zheng Ran					2. Issuer Name and Ticker or Trading Symbol Caribou Biosciences, Inc. [CRBU]					(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024							Officer below)	(give title	Other (below)	specify
C/O CARIBOU BIOSCIENCES, INC. 2929 7TH STREET, SUITE 105				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street)	LEY C	Α	94710										led by More t	han One Repo	
(City)			(Zip)	_ R			` ,	Transac			•				
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							d to			
		Tab	le I - Non-De	rivativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		Code (Instr. 5)			5. Amou Securitie Beneficia Owned F Reported	s Feally (Discoloring (I)		7. Nature of Indirect Beneficial Ownership				
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, T ecurity or Exercise (Month/Day/Year) if any			ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to purchase Common Stock	\$6.81	02/20/2024		A		39,500		(1)	02/19/2034	Common Stock	39,500	\$0	39,500	D	

Explanation of Responses:

1. One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Remarks:

/s/ Barbara G. McClung, as attorney-in-fact

02/22/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.